Stock Market Reviews

ENVB (Enveric Biosciences, Inc.) News

Get the latest news, insights, and market updates on ENVB (Enveric Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
  CAMBRIDGE, Mass., November 14, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the third quarter ended September 30, 2025, and provided a comprehensive business update.
  Nov 14, 2025 - $ENVB
• Enveric Biosciences Announces Reverse Stock Split
  CAMBRIDGE, Mass., October 23, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 12 pre-split shares. The reverse stock split will become effective at 8:00 a.m., New York time, on Tuesday, October 28, 2025. Enveric’s co
  Oct 23, 2025 - $ENVB
• Weekly Roundup on the Cannabis Sector & Psychedelic Sector
  Key Takeaways; Cannabis Sector Ayr Wellness Advanced Debt Restructuring While Expanding Operations with New Florida Facility Vireo Growth Acquired Schwazze Debt in $62 Million Deal Tilray Expanded into Panama Through Joint Venture, Strengthening its Global Cannabis Footprint Key Takeaways; Psychedelic Sector Enveric Biosciences Expanded Neuroplastogenic Patent Estate and Strengthened IP Defense Amid Strategic Initiatives Algernon […]
  Oct 19, 2025 - $ENVB
• Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
  CAMBRIDGE, Mass., October 16, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the issuance of its 23rd patent from the United States Patent and Trademark Office (USPTO) for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental heal
  Oct 16, 2025 - $ENVB
• AbbVie's Bretisilocin Hit With Enveric IP Claim
  Shares pop 20% as legal fight looms
  Oct 15, 2025 - $ENVB
• Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
  CAMBRIDGE, Mass., October 15, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals (Gilgamesh) against Enveric’s issued U.S. Patent No. 12,138,276 (the’276 patent,) entitled,
  Oct 15, 2025 - $ENVB
• Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
  Investing.com -- Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed to be acquired by AbbVie for up to $1.2 billion, Investing.com has learned.
  Oct 15, 2025 - $ENVB
• Enveric Biosciences to Explore Digital Asset Treasury Opportunities
  CAMBRIDGE, Mass., October 14, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that its Board of Directors has authorized the Company’s Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities. Any such opportunities will be subject to further
  Oct 14, 2025 - $ENVB
• Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
  CAMBRIDGE, Mass., October 02, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced significant progress in the chemistry, manufacturing, and controls (CMC) development of its lead candidate, EB-003. Important steps in scaling production and preparing the drug for required regulatory activities have been achieved, advancing EB-003
  Oct 2, 2025 - $ENVB
• Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
  CAMBRIDGE, Mass., September 18, 2025--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 sha
  Sep 18, 2025 - $ENVB